Vyluma Announces Acceptance of Drug Application for NVK002 by China’s National Medical Products Administration (NMPA)
BRIDGEWATER, N.J., Jan. 29, 2025 (GLOBE NEWSWIRE) -- Vyluma, Inc. (“Vyluma”), a biopharmaceutical company advancing novel treatments for refractive errors, announced today that the National Medical Products Administration (NMPA) of China has accepted the …